Phase Ib safety trial of CVX-060, an intravenous humanized monoclonal CovX body inhibiting angiopoietin 2 (Ang-2), with axitinib in patients with previously treated metastatic renal cell cancer (RCC). Abstract No: 2533

• Autoři: GOLLERKERI Ashwin; GORDON Michael S.; BURKE John M.; HAUKE Ralph; TOMÁŠEK Jiří; DONALD Richards A
• Rok publikování: 2013
• Druh: Další prezentace na konferencích